Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (NYSE: LLY) stock movement is driven by several developments over the last 24–36 hours:

• Positive Sentiment: Updated clinical data suggest Lilly’s SGLT2 inhibitor study shows promise in managing anemia in chronic kidney disease patients, potentially expanding its diabetes and renal care franchise. Eli Lilly’s New Study on SGLT2 Inhibitors: A Potential Game-Changer for CKD Anemia Management
• Positive Sentiment: Lilly teamed up with the Association of Physicians of India to launch “Obesity Gurukul,” a continuing medical education program to train Indian healthcare providers in obesity care, strengthening its footprint in a key emerging market. Eli Lilly collaborate with API to launch obesity Gurukul for obesity care in India
• Positive Sentiment: Guggenheim boosted its price target on LLY shares to $942, reflecting strong confidence in Lilly’s late-stage pipeline and robust revenue growth outlook. Eli Lilly and Company (NYSE:LLY) Given New $942.00 Price Target at Guggenheim
• Neutral Sentiment: Goldman Sachs raised its S&P 500 year-end forecast and highlighted three top picks—KSS, NTLA and GOGO—but did not include LLY, underscoring broad market optimism without a direct call on Lilly. Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
• Neutral Sentiment: A high-profile breast cancer awareness campaign at the WNBA All-Star Weekend in Lilly’s home state boosts brand visibility but has limited near-term revenue impact. Eli Lilly balls out for breast cancer awareness at WNBA All-Star weekend
• Neutral Sentiment: Long-term forecasts from 2025–2030 reaffirm Lilly’s strong historical gains but offer no new catalysts, serving mainly as context for patient investors. Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025)
• Neutral Sentiment: Increased search activity for LLY on Zacks.com highlights growing retail interest but reflects curiosity rather than a specific news catalyst. Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
• Neutral Sentiment: A joint financial survey with Bayer AG provides comparative metrics but offers no new guidance from either company, limiting its immediate significance. Eli Lilly and Company (NYSE:LLY) & Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Financial Survey
• Negative Sentiment: Leerink Partners cut its Q2 2025 EPS forecast from $5.54 to $5.40, signaling potential near-term earnings headwinds. Q2 Earnings Forecast for LLY Issued By Leerink Partnrs